El Salvador vs Panama: Average cost of multi drug-resistant tuberculosis treatment
El Salvador
574 constant 2022 US$
in 2024
Panama
572 constant 2022 US$
in 2024
El Salvador rank
73rd
Panama rank
74th
Average cost of multi drug-resistant tuberculosis treatment over time
- El Salvador
- Panama
How they compare
El Salvador currently reports 574 constant 2022 US$ against 572 constant 2022 US$ in Panama, a difference of 2 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Panama ahead.
El Salvador ranks 73rd and Panama ranks 74th of 92 countries.
Across the 2 decades both report, El Salvador averaged higher in 1 and Panama in 1.
Head to head by decade
| Decade | El Salvador | Panama | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 576 constant 2022 US$ | 5,436 constant 2022 US$ | 4,860 constant 2022 US$ | Panama |
| 2020s | 3,004 constant 2022 US$ | 1,288 constant 2022 US$ | 1,716 constant 2022 US$ | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, El Salvador or Panama?
- El Salvador, at 574 constant 2022 US$ against 572 constant 2022 US$ in Panama as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between El Salvador and Panama?
- 2 constant 2022 US$, with El Salvador ahead.
- How many years of comparable data are there for El Salvador and Panama?
- 5 years are reported by both, from 2017 to 2024.
- How do El Salvador and Panama rank globally for average cost of multi drug-resistant tuberculosis treatment?
- El Salvador ranks 73rd and Panama ranks 74th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.